{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:16:26Z","timestamp":1788243386169,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40265-026-02358-2","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:54:45Z","timestamp":1785394485000},"page":"1571-1576","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acoziborole: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7260-8131","authenticated-orcid":false,"given":"Aisling","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"issue":"10482","key":"2358_CR1","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(25)00107-2","volume":"405","author":"V Lejon","year":"2025","unstructured":"Lejon V, Lindner AK, Franco JR. Human African trypanosomiasis. Lancet. 2025;405(10482):937\u201350.","journal-title":"Lancet"},{"key":"2358_CR2","unstructured":"World Health Organization. Guidelines for the treatment of human African trypanosomiasis. 2024. https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/4da65589-ada0-40de-837c-1033af9733c4\/content. Accessed 16 Jun 2026."},{"issue":"1","key":"2358_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0010047","volume":"16","author":"JR Franco","year":"2022","unstructured":"Franco JR, Cecchi G, Paone M, et al. The elimination of human African trypanosomiasis: achievements in relation to WHO road map targets for 2020. PLoS Negl Trop Dis. 2022;16(1):e0010047.","journal-title":"PLoS Negl Trop Dis"},{"key":"2358_CR4","unstructured":"Sanofi Winthrop Industrie. Acoziborole Winthrop: EU prescribing information. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-product-information\/acoziborole-winthrop-product-information_en.pdf. Accessed 16 Jun 2026."},{"key":"2358_CR5","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. CHMP summary of positive opinion for Acoziborole Winthrop. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-smop-initial\/chmp-summary-positive-opinion-acoziborole-winthrop_en.pdf. Accessed 16 Jun 2026."},{"key":"2358_CR6","unstructured":"European Medicines Agency. New single-dose oral treatment for human African trypanosomiasis (sleeping sickness) [media release]. 27 Feb 2026. https:\/\/www.ema.europa.eu\/en\/news\/new-single-dose-oral-treatment-human-african-trypanosomiasis-sleeping-sickness."},{"key":"2358_CR7","unstructured":"Sanofi. Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness [media release]. 27 Feb 2026. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2026\/2026-02-27-10-55-51-3246379."},{"key":"2358_CR8","unstructured":"Pfizer. Pfizer completes acquisition of Anacor [media release]. 24 Jun 2016. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_completes_acquisition_of_anacor."},{"key":"2358_CR9","unstructured":"DNDi. TB Alliance and DNDi announce collaborations with Anacor to apply boron technology to identify new medicines for neglected diseases [media release]. 27 May 2009. https:\/\/dndi.org\/press-releases\/2009\/tb-alliance-and-dndi-announce-collaborations-with-anacor-to-apply-boron-technology-to-identify-new-medicines-for-neglected-diseases\/."},{"key":"2358_CR10","unstructured":"DNDi. DNDi research and development portfolio: sleeping sickness: acoziborole. 2026. https:\/\/dndi.org\/research-development\/portfolio\/acoziborole\/. Accessed 16 Jun 2026."},{"key":"2358_CR11","unstructured":"DNDi. Innovative partnership advances novel drug candidate to combat sleeping sickness [media release]. 28 Jun 2011. https:\/\/dndi.org\/press-releases\/2011\/oxaborolesbio\/."},{"key":"2358_CR12","unstructured":"DNDi. Innovative single-dose oral sleeping sickness treatment to be co-developed by Sanofi and DNDi partnership [media release]. 4 Sep 2020. https:\/\/dndi.org\/press-releases\/2020\/innovative-single-dose-oral-sleeping-sickness-treatment-to-be-co-developed-by-sanofi-and-dndi\/."},{"key":"2358_CR13","unstructured":"Sanofi. Acoziborole: investigational single-dose oral treatment raises hope for elimination of sleeping sickness in Africa [media release]. 30 Nov 2022. https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2022\/2022-11-30-07-00-00-2564640."},{"key":"2358_CR14","unstructured":"Anacor Pharmaceuticals LLC. Boron containing small molecules as antiprotozoal agents [patent number US9449994]. 2010."},{"issue":"1","key":"2358_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s13104-022-06258-y","volume":"15","author":"A Waithaka","year":"2022","unstructured":"Waithaka A, Clayton C. Clinically relevant benzoxaboroles inhibit mRNA processing in Trypanosoma brucei. BMC Res Notes. 2022;15(1):371.","journal-title":"BMC Res Notes"},{"issue":"38","key":"2358_CR16","doi-asserted-by":"publisher","first-page":"9616","DOI":"10.1073\/pnas.1807915115","volume":"115","author":"RJ Wall","year":"2018","unstructured":"Wall RJ, Rico E, Lukac I, et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc Natl Acad Sci U S A. 2018;115(38):9616\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2358_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.105302","volume":"25","author":"A Sharma","year":"2022","unstructured":"Sharma A, Cipriano M, Ferrins L, et al. Hypothesis-generating proteome perturbation to identify NEU-4438 and acoziborole modes of action in the African trypanosome. iScience. 2022;25(11):105302.","journal-title":"iScience"},{"issue":"6","key":"2358_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001151","volume":"5","author":"RT Jacobs","year":"2011","unstructured":"Jacobs RT, Nare B, Wring SA, et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl Trop Dis. 2011;5(6):e1151.","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"2358_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1017\/S003118201300098X","volume":"141","author":"S Wring","year":"2014","unstructured":"Wring S, Gaukel E, Nare B, et al. Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of stage 2 human African trypanosomiasis. Parasitology. 2014;141(1):104\u201318.","journal-title":"Parasitology"},{"issue":"4","key":"2358_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S1473-3099(22)00660-0","volume":"23","author":"VKB Kumeso","year":"2023","unstructured":"Kumeso VKB, Kalonji WM, Rembry S, et al. Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2\/3 trial. Lancet Infect Dis. 2023;23(4):463\u201370.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2358_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s40262-023-01216-8","volume":"62","author":"A Tarral","year":"2023","unstructured":"Tarral A, Hovsepian L, Duvauchelle T, et al. Determination of the optimal single dose treatment for acoziborole, a novel drug for the treatment of human African trypanosomiasis: first-in-human study. Clin Pharmacokinet. 2023;62(3):481\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"2358_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00580-25","volume":"69","author":"J-Y Gillon","year":"2025","unstructured":"Gillon J-Y, Simon F, Sidhu S, et al. Mass balance, pharmacokinetics, metabolism, and excretion of radiolabeled acoziborole, a potential novel treatment for human African trypanosomiasis, following single microtracer oral dose to humans. Antimicrob Agents Chemother. 2025;69(11):e0058025.","journal-title":"Antimicrob Agents Chemother"},{"key":"2358_CR23","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use. Acoziborole Winthrop: public assessment report. 2026. https:\/\/www.ema.europa.eu\/en\/documents\/outside-eu-assessment-report\/acoziborole-winthrop-public-assessment-report_en.pdf. Accessed 16 Jun 2026."},{"key":"2358_CR24","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier: NCT05256017. 2022. https:\/\/clinicaltrials.gov\/study\/NCT05256017. Accessed 16 Jun 2026."},{"key":"2358_CR25","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier: NCT05433350. 2026. https:\/\/clinicaltrials.gov\/study\/NCT05433350. Accessed 16 Jun 2026."},{"key":"2358_CR26","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier: NCT06356974. 2026. https:\/\/clinicaltrials.gov\/study\/NCT06356974. Accessed 16 Jun 2026."},{"issue":"23","key":"2358_CR27","first-page":"1","volume":"5","author":"E Nicco","year":"2025","unstructured":"Nicco E, Lejon V, Mwamba Miaka E, et al. The STROGHAT study protocol: an intervention study to evaluate safety, effectiveness and feasibility of treating gambiense HAT seropositive subjects with acoziborole. Open Res Eur. 2025;5(23):1\u201322.","journal-title":"Open Res Eur."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02358-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02358-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02358-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T06:02:28Z","timestamp":1788242548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02358-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2358"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02358-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Aisling McGuigan is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}